Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
0
Authors
Toni Choueiri
Toni Choueiri•Jaroslav Hájek•Thomas Powles
Published
August 18, 2021
Abstract
Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence.
